Established in 1968 in India, Lupin's vision is to be an innovation led global pharmaceutical company.
Lupin is amongst the top 5 Indian pharmaceutical companies with world class EU GMP and USFDA approved manufacturing facilities.
Lupin aims to be the partner of choice for economic and high quality pharmaceutical development and manufacture. The partner of choice for many pharmaceutical majors,
- out-licensing and supply arrangements for its generic products / dossiers (CTD format)
- supply of APIs
- generic dossier co-development
- life cycle extension through our range of novel drug delivery systems
- custom synthesis and contract research & development
A drive for excellence through technology and research has earned Lupin a position in the top league of pharmaceutical companies from India.
Lupin has become a global leader in the anti-TB segment and one of the world's largest integrated manufacturers of cephalosporins, having sterile injectable, tablet, capsule and suspensions for reconstitution forms available.
Lupin also leads in the manufacture of cardiovascular drugs, such as Lisinopril, Benazepril, Ramipril, Quinapril, Perindopril and Trandolopril; has significant fermentation capabilities producing drugs from the Statin class; and a range of developments spanning Sartans and Prazoles.
Lupin has a large generic portfolio of such molecules available for licensing. Among the largest pharmaceutical exporters from India, Lupin caters to the global generic market and has developed a branded presence in the US paediatric segment. The company's R&D Park, in Pune, conducts leading-edge research into Generics, NCEs, Novel Drug Delivery Systems and Phytomedicines.
Lupin's Innovation Cell is focused on the development of drug delivery systems including taste-masking, chewable, tablet to liquid, invasive to non-invasive, oral controlled release and others.
- Core Sales Territory:
Global Regulated Markets
- Formed: 1968
- Number of employees: 10000